Welcome to our dedicated page for Addex Therapeutics news (Ticker: ADXN), a resource for investors and traders seeking the latest updates and insights on Addex Therapeutics stock.
Addex Therapeutics Ltd (ADXN) is a clinical-stage pharmaceutical company focused on small-molecule allosteric modulators, particularly for neurological disorders. This news page aggregates coverage related to Addex Therapeutics, reflecting its activities in allosteric modulation-based drug discovery and development and its role as a NASDAQ Capital Market–listed issuer.
Company information highlights that Addex Therapeutics operates in one segment centered on the discovery, development and commercialization of small-molecule pharmaceutical products. News about the company can include updates on its allosteric modulator programs, collaborations that support its research, and announcements that are later furnished to the U.S. Securities and Exchange Commission on Form 6-K.
Public reports describe a long-standing research collaboration between Addex Therapeutics and Enamine Ltd, in which Enamine provides medicinal chemistry, pharmacology and ADME/PK capabilities for small molecule CNS drug discovery programs. Developments in such collaborations, as well as press releases incorporated into SEC filings, are typical examples of items that may appear in the Addex Therapeutics news feed.
Investors and observers can use this page to follow press releases referenced in Form 6-K submissions, updates on the company’s allosteric modulator platform, and other disclosures that Addex Therapeutics chooses to make public. For users tracking ADXN, this page offers a centralized view of company-specific news that complements the formal information contained in its SEC filings and other regulatory documents.
Enamine Ltd. has extended its collaboration with Addex Therapeutics Ltd (ADXN), enhancing its drug discovery services in CNS small molecules. Enamine will utilize its extensive resources and expertise in medicinal chemistry and pharmacology to support Addex's research programs under a Full Time Equivalent (FTE) model. Enamine's innovation and large collection of over 225,000 building blocks are expected to positively impact Addex's lead finding activities. This partnership builds upon years of successful collaboration and will continue to foster advancements in drug discovery.
FAQ
What is the current stock price of Addex Therapeutics (ADXN)?
What is the market cap of Addex Therapeutics (ADXN)?
